PF-Atlas › Clinical Trials › NCT04948203
Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
Sirolimus · Phase 2
Registry ID
NCT04948203
Phase
Phase 2
Status
Active, not recruiting
Drug / intervention
Sirolimus
Sponsor
University of Chicago
Start
2021-07-09
About this trial
Sirolimus is evaluated in NCT04948203, a Phase 2 idiopathic pulmonary fibrosis study sponsored by University of Chicago. Current status: Active, not recruiting.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT04948203 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.